Monograph of Propylthiouracil

Introduction

Propylthiouracil (PTU) is a thioamide antithyroid agent employed in the management of thyrotoxicosis. It functions primarily by inhibiting thyroid hormone synthesis and by reducing peripheral conversion of thyroxine (T4) to triiodothyronine (T3). This compound has played a pivotal role in endocrine pharmacotherapy since its introduction in the mid‑20th century and remains an essential option in specific clinical situations, such as thyroid storm and pregnancy‑associated thyrotoxicosis.

Historically, PTU was first synthesized in 1935 and became widely available in the 1950s. Early use focused on its ability to block iodide organification, a mechanism distinct from that of other thioamides such as methimazole. Over the decades, its indications have expanded and refined, informed by evolving safety data and comparative efficacy studies.

Understanding PTU is critical for clinicians and pharmacists because its pharmacodynamic profile, contraindications, and monitoring requirements differ markedly from other antithyroid drugs. Mastery of its principles informs safe prescribing, therapeutic monitoring, and management of adverse events.

Learning Objectives

• Describe the mechanism of action of PTU at the cellular and systemic levels.
• Explain the pharmacokinetic properties of PTU, including absorption, distribution, metabolism, and elimination.
• Identify indications, contraindications, and monitoring parameters for PTU therapy.
• Apply knowledge of PTU to the management of specific clinical scenarios, including thyroid storm and pregnancy.
• Compare PTU with alternative antithyroid agents in terms of efficacy, safety, and therapeutic context.

Fundamental Principles

Core Concepts and Definitions

PTU is classified as an organo‑sulfur compound, specifically a thiourea derivative. Its therapeutic action is twofold: inhibition of thyroid peroxidase (TPO), which catalyzes iodide oxidation and organification, and inhibition of the type 1 iodothyronine deiodinase, responsible for the peripheral conversion of T4 to the more active T3. The latter effect is unique among antithyroid medications and contributes to its rapid reduction of circulating T3 levels.

Theoretical Foundations

Thyroid hormone synthesis commences with iodide uptake via the sodium‑iodide symporter (NIS) into thyrocytes. Iodide is then oxidized to iodine by TPO, and subsequently organified onto tyrosyl residues within thyroglobulin. PTU competitively inhibits TPO, thereby preventing both iodide oxidation and organification. Additionally, PTU binds and inactivates deiodinases, reducing the conversion of T4 to T3, which accounts for its pronounced effect on serum T3 concentrations.

Key Terminology

• Thyrotoxicosis: Excessive thyroid hormone levels leading to systemic hypermetabolism.
• Thyroid storm: Life‑threatening exacerbation of thyrotoxicosis characterized by fever, tachycardia, and delirium.
• Type 1 iodothyronine deiodinase (D1): Enzyme mediating peripheral conversion of T4 to T3.
• Half‑life (t_1/2): Time required for plasma concentration to decline by 50 %.
• Area under the curve (AUC): Integral of the concentration‑time curve, representing overall drug exposure.

Detailed Explanation

Mechanism of Action

PTU exerts its antithyroid effect by two principal mechanisms: (1) inhibition of TPO, which blocks iodide oxidation and organification of thyroglobulin; (2) inhibition of D1, reducing peripheral conversion of T4 to T3. The dual action yields a faster decline in T3 levels compared to other agents that act solely on synthesis. In vitro studies demonstrate that PTU binds to the active site of TPO, forming a covalent complex that is irreversibly inactivated. The inhibition of D1 is mediated through direct interaction with the selenocysteine residue in the enzyme’s catalytic center, thereby obstructing deiodination activity.

Pharmacokinetics

Absorption

PTU is well absorbed after oral administration, with an estimated bioavailability of 90 %. Peak plasma concentrations (C_max) are typically reached within 1 – 2 hours (t_max) post‑dose. Food intake may slightly delay absorption but does not significantly alter overall bioavailability.

Distribution

After absorption, PTU distributes extensively throughout body tissues. Plasma protein binding is moderate (≈ 45 %). The volume of distribution (V_d) approximates 0.4 L kg^-1, indicating moderate tissue penetration. PTU’s lipophilicity facilitates crossing of the blood‑brain barrier, which may contribute to central nervous system side effects observed in rare cases.

Metabolism

PTU undergoes hepatic metabolism primarily via glucuronidation. Minor pathways include sulfation and oxidation. The metabolites are generally inactive and are excreted unchanged. Because hepatic function directly influences clearance, patients with hepatic impairment may exhibit prolonged drug exposure.

Elimination

Renal excretion constitutes the principal route of PTU elimination. The terminal half‑life (t_1/2) ranges from 1 – 2 hours in healthy adults, extending to 6 – 8 hours in patients with renal dysfunction. Clearance (Cl) can be approximated by the equation:

Cl = Dose ÷ AUC

or, expressed in terms of half‑life and volume of distribution:

Cl = (0.693 × V_d) ÷ t_1/2.

These relationships allow calculation of drug exposure and facilitate dose adjustments in special populations.

Factors Affecting Pharmacokinetics and Pharmacodynamics

• Age: Elderly patients may exhibit reduced hepatic clearance and altered volume of distribution, necessitating dosage consideration.
• Renal Function: Impaired glomerular filtration rate (GFR) prolongs t_1/2 and lowers clearance, increasing risk of accumulation.
• Hepatic Function: Hepatic impairment reduces glucuronidation capacity, potentially elevating systemic exposure.
• Drug Interactions: Concomitant use of inhibitors or inducers of glucuronidation (e.g., rifampin, phenytoin) can alter PTU clearance.
• Pregnancy: Physiological changes increase renal clearance and reduce serum albumin, affecting distribution and elimination.

Clinical Significance

Therapeutic Indications

PTU is indicated for:

• Acute management of thyrotoxicosis, particularly when rapid reduction of T3 is desired.
• Preoperative stabilization of patients with Graves disease undergoing thyroidectomy.
• Management of thyroid storm, where immediate suppression of hormone synthesis and peripheral conversion is critical.
• Pregnancy‑associated thyrotoxicosis, especially in the first trimester, due to its lower fetal transfer compared with methimazole.

Practical Applications

Standard dosing regimens include an initial loading dose of 200 mg orally every 6 hours, followed by maintenance doses ranging from 50 mg to 300 mg daily, divided into multiple administrations. Adjustments are guided by serial measurements of free T4 (FT4), free T3 (FT3), and TSH, along with hepatic transaminases and platelet counts. The goal is to achieve euthyroidism while minimizing adverse events.

Monitoring Parameters

• Hormonal Levels: FT4 and FT3 should be reassessed every 1 – 2 weeks during initiation and titration, and monthly thereafter.
• Hepatic Function: ALT and AST are monitored biweekly during the first month, then monthly.
• Hematological Profile: Platelet count is checked weekly during the first month to detect agranulocytosis, and monthly thereafter.
• Clinical Signs: Symptom resolution (e.g., heart rate, temperature, tremor) is evaluated clinically, supplementing laboratory data.

Adverse Effects and Safety Profile

Common adverse events include gastrointestinal upset, rash, and metallic taste. Rare but serious complications encompass agranulocytosis, hepatotoxicity, and hypersensitivity reactions. These risks underscore the necessity of diligent monitoring and patient education. The incidence of agranulocytosis is approximately 0.1 %–0.2 % with PTU, a figure comparable to that observed with methimazole. Hepatotoxicity may present as elevated transaminases or fulminant hepatic failure; early detection is critical.

Clinical Applications/Examples

Case Scenario 1: 35‑Year‑Old Female with Graves Disease

A 35‑year‑old woman presents with tremor, weight loss, and exophthalmos. Laboratory evaluation reveals FT4 of 25 pmol L^-1 (normal 9–18) and FT3 of 7.8 pmol L^-1 (normal 2.3–4.2). She is diagnosed with Graves disease. Initial management includes PTU 200 mg every 6 hours for one week, followed by 150 mg daily. Over the next 4 weeks, FT4 declines to 14 pmol L^-1 and FT3 to 3.2 pmol L^-1. Platelet count remains stable, and hepatic enzymes are within normal limits. The patient is transitioned to oral methimazole for long‑term maintenance, as PTU is reserved for acute indications or pregnancy.

Case Scenario 2: 65‑Year‑Old Male with Toxic Multinodular Goiter

A 65‑year‑old man with a history of hypertension presents with rapid heart rate and heat intolerance. FT4 is 28 pmol L^-1 and FT3 is 8.5 pmol L^-1. He is started on PTU 300 mg daily, divided into two doses. After two weeks, FT4 falls to 18 pmol L^-1 and FT3 to 4.5 pmol L^-1, but the patient develops mild transaminitis (ALT 65 U L^-1). PTU is discontinued, and the patient is switched to propylthiouracil‑sparing therapy with a higher dose of methimazole, monitoring liver enzymes closely. The patient’s symptoms resolve, and a definitive surgical plan is pursued.

Problem‑Solving Approach: Dose Adjustment in Renal Impairment

A 58‑year‑old patient with chronic kidney disease (eGFR 30 mL min^-1 1.73 m^-2) requires PTU for thyrotoxicosis. Because renal clearance contributes significantly to PTU elimination, a dose reduction to 50 mg twice daily is prudent. Monitoring of FT4, FT3, and transaminases is intensified, with dose reassessment after 2 weeks. If FT4 remains elevated, a modest increase to 75 mg twice daily may be considered, provided hepatic and hematologic parameters remain acceptable.

Summary / Key Points

• Propylthiouracil inhibits thyroid peroxidase and type 1 deiodinase, leading to decreased synthesis of T4/T3 and reduced peripheral conversion of T4 to T3.
• Key pharmacokinetic parameters: bioavailability ≈ 90 %, t_max 1 – 2 h, t_1/2 1 – 2 h (normal), clearance ≈ (0.693 × V_d) ÷ t_1/2.
• Indications include acute thyrotoxicosis, thyroid storm, pregnancy‑associated thyrotoxicosis, and pre‑operative control of Graves disease.
• Monitoring should include FT4/FT3, TSH, hepatic transaminases, and platelet count; adverse events such as agranulocytosis and hepatotoxicity warrant prompt evaluation.
• Clinical decision‑making requires balancing efficacy (rapid T3 reduction) against safety risks; dose adjustments are guided by renal and hepatic function.

Clinical pearls: Early initiation of PTU in thyroid storm can markedly improve survival; in pregnancy, PTU is preferred in the first trimester due to lower teratogenic risk; regular laboratory surveillance is indispensable to prevent life‑threatening complications.

References

1. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.